ClinicalTrials.gg
RecruitingNCT07577973SAPHUpdated Nov 4, 2026

The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension

An interventional study of Real Acupressure and sham acupressure in PRIMARY HYPERTENSION, sponsored by Abant Izzet Baysal University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Abant Izzet Baysal University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 4, 2026Now RecruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Essential Hypertension with a site in Turkey — 6 open to participants now, 6 under way, none of them phase 3. Essential Hypertension · Turkey.

Planned enrollment
14th of 19
72 · median 130
Started
2026
with 1 other
No phase
11 of 21
5 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
Abant Izzet Baysal University

Among the 21 studies in Essential Hypertension with a site in Turkey, this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 21st registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

6 of the 21 studies in Essential Hypertension with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Essential Hypertension with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial examines the effects of nurse-led self-acupressure at HT7, LI4, PC6, and EX3 points on blood pressure, stress, and well-being in adults with primary hypertension. Participants are randomized to real acupressure, sham acupressure, or usual care groups for 2 weeks.

03

Conditions studied

  • PRIMARY HYPERTENSION

Keywords

  • Acupressure Hypertension Self-care Nursing Stress Well-being Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-65 years
  2. Diagnosed with primary hypertension (Stage 1 or 2)
  3. Systolic blood pressure 130-179 mmHg or diastolic 80-109 mmHg
  4. Taking antihypertensive medication
  5. Able to understand and communicate in Turkish
  6. Willing to provide written

Exclusion criteria

Exclusion Criteria:

  1. Secondary hypertension
  2. Pregnancy or lactation
  3. Severe cardiovascular disease (heart failure, myocardial infarction within 6 months)
  4. Stroke history within 6 months
  5. Skin lesions or infection at acupressure sites (HT7, LI4, PC6, EX3)
  6. Peripheral neuropathy affecting sensation
  7. Current use of anticoagulant therapy
  8. Participation in another clinical trial within 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Real Acupressure Group

    participants receive acupressure on bilateral HT7,LI4,PC6 EX3 points. pressure applied for 15 seconds per point, 3 days per week, for 2 weeks

    Behavioral: Real Acupressure

  • Sham comparator
    sham/placebo

    Participants receive sham acupressure on non-acupoints located 1-1.5 cm away from HT7, LI4 , PC6, and EX3 points. Pressure applied for 15 seconds per site, 3 days per week, for 2 weeks to maintain participant blinding

    Behavioral: sham acupressure

  • Active comparator
    control

    Participants receive usual care for hypertension including prescribed antihypertensive medications and routine clinical nursing follow-up for 2 weeks. No acupressure intervention applied.

    Other: Usual Care

Interventions

  • BehavioralReal Acupressure

    Acupressure applied to HT7 (Shenmen), LI4 (Hegu), PC6 (Neiguan) bilaterally, and EX3 (Yintang). Pressure applied for 15 seconds per point, 3 days per week for 2 weeks by trained researcher. Total session duration approximately 1 minute.

  • Behavioralsham acupressure

    light pressure applied to non-acupoint sites 1-1.5 cm from HT7İLI4,PC6 and EX3 points for 15 seconds per site,3 days per week for 2 weeks

  • OtherUsual Care

    Standard hypertension management including prescribed antihypertensive medication and routine clinical nursing follow-up for 2 weeks. No acupressure applied.

06

What researchers measure

Primary outcomes

  1. change in blood pressure

    change from baseline in systolic and diastolic blood pressure measured using an automated office blood pressure monitor at 2 weeks

    Time frame: baseline and week 2

Secondary outcomes

  1. change in perceived stress

    Change from baseline in Perceived Stress Scale-14 (PSS-14) total score at 2 weeks. Scores range from 0 to 56, with higher scores indicating greater perceived stress

    Time frame: baseline, week 2

  2. change in mental well-being

    Change from baseline in Warwick-Edinburgh Mental Well-being Scale (WEMWBS) total score at 2 weeks. Scores range from 14 to 70, with higher scores indicating better mental well-being

    Time frame: baseline, week 2

07

Study locations

1 of 1 sites recruiting
  • A Family Health Center in Duzce
    Center, Düzce, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant confidentiality as stated in the informed consent form approved by the ethics committee. Data will only be accessible to the study team for the purposes of this study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 2 months after the start.

Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 2 months is below that.

Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Jun 2026 → Sep 2026, primary completion Sep 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 11, 2026
StartActual
Sep 7, 2026was Jun 2026
Primary completionEst.
Dec 1, 2026was Sep 2026
CompletionEst.
Dec 30, 2026was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • A Family Health Center in Duzce · Center, Turkey (Türkiye)
Show 1 removed
  • A Family Health Center in Duzce · Düzce, Turkey (Türkiye)
Nov 4, 2026
Start date
Jun 2026→Sep 7, 2026 (actual)
Nov 4, 2026
Primary completion
Sep 2026→Dec 1, 2026
Nov 4, 2026
Study completion
Oct 2026→Dec 30, 2026
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • A Family Health Center in Duzce · Center, Turkey (Türkiye)
    Show 1 removed
    • A Family Health Center in Duzce · Düzce, Turkey (Türkiye)
    Start date Jun 2026→Sep 7, 2026 (now actual)
    Primary completion Sep 2026→Dec 1, 2026
    Study completion Oct 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07577973
Responsible party
Saadet Can Çiçek (Asst. Prof.Saadet Can Cicek,Phd, Abant Izzet Baysal University) — Principal investigator
First posted
May 11, 2026
Start date
Sep 7, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 4, 2026

Study contacts

Seymanur Ozdemir Arslan, MSc,Phd Candidate
Contact
seymanurarslan@duzce.edu.tr
+90 0380 523 7827
Saadet Can Cicek, Associate Professor,PhD
principal investigator · Abant Izzet Baysal University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion